

TYR RABBIT PAB

货号: S216871

产品全名: TYR 兔多抗

基因符号: ATN; CMM8; OCA1; OCA1A; OCA1A; SHEP3

UNIPROT ID: P14679 (Gene Accession - BC027179)

背景: The enzyme encoded by this gene catalyzes the first 2 steps, and at least 1 subsequent step, in the conversion of tyrosine to melanin. The enzyme has both tyrosine hydroxylase and dopa oxidase catalytic activities, and requires copper for function. Mutations in this gene result in oculocutaneous albinism, and nonpathologic polymorphisms result in skin pigmentation variation. The human genome contains a pseudogene similar to the 3' half of this gene.

抗原: Fusion protein of human TYR

经过测试的应用: ELISA, WB, IHC

推荐稀释比: IHC: 50-200;WB: 1000-5000;ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Metabolism


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human colorectal cancer tissue using 216871(TYR Antibody) at a dilution of 1/80(Cytoplasm).




In comparison with the IHC on the left, the same paraffin-embedded Human colorectal cancer tissue is first treated with the fusion protein and then with 216871(Anti-TYR Antibody) at dilution 1/80.



The image on the left is immunohistochemistry of paraffin-embedded Human breast cancer tissue using 216871(Anti-TYR Antibody) at a dilution of 1/80.



In comparison with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with fusion protein and then with D221392(Anti-TYR Antibody) at dilution 1/80.



Gel: 8%SDS-PAGE, Lysate: 40 µg;
 Lane 1-3: HepG2, HUVEC, Jurkat cell lysates;
 Primary antibody: 216871(TYR Antibody) at dilution 1/1600;
 Secondary antibody: HRP-conjugated Goat anti rabbit IgG at 1/5000 dilution;
 Exposure time: 1 minute



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
